- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.02. | Cumulus Neuroscience Enters Japanese Market to Advance Novel Cognitive Biomarkers with New Customer Shionogi & Co., Ltd. | 363 | PR Newswire | BELFAST, Northern Ireland, Feb. 10, 2026 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and... ► Artikel lesen | |
| 02.02. | Shionogi & Co. GAAP EPS of ¥188.00, revenue of ¥500B | 7 | Seeking Alpha | ||
| 30.01. | Shionogi & Co., Ltd. Reports Rise In Nine Months Profit | 368 | AFX News | TOKYO (dpa-AFX) - Shionogi & Co., Ltd. (SGIOF) reported earnings for its nine months that Increased, from last yearThe company's bottom line came in at JPY158.225 billion, or JPY185.91 per share.... ► Artikel lesen | |
| 25.01. | Pfizer to Exit ViiV Healthcare as GSK and Shionogi Reshape Ownership | 25 | Insider Monkey | ||
| 20.01. | Pfizer exits GSK majority-owned ViiV Healthcare; Shionogi raises stake | 24 | Seeking Alpha | ||
| 20.01. | Shionogi expands ViiV Healthcare stake by $2.13bn as Pfizer sells up | 4 | Pharmaceutical Technology | ||
| 20.01. | Pfizer sells its stake in GSK's ViiV for $1.9B, with Shionogi upping its ante in the HIV-focused company | 21 | FiercePharma | ||
| SHIONOGI & CO LTD ADR Aktie jetzt für 0€ handeln | |||||
| 20.01. | Shionogi stockt Anteil an ViiV Healthcare auf - Pfizer steigt aus | 28 | Investing.com Deutsch | ||
| 22.12.25 | ALS med Radicava to change hands as Shionogi inks $2.5B buyout | 3 | FiercePharma | ||
| 04.12.25 | Pfizer, GSK, Shionogi sponsor London run of musical about antimicrobial resistance | 9 | FiercePharma | ||
| 30.10.25 | Shionogi Announces Corporate Reorganization Following Japan Tobacco Pharma Merger | 800 | AFX News | TOKYO (dpa-AFX) - Shionogi & Co., Ltd. Thursday announced it will implement a corporate reorganization and several personnel reassignments, effective December 1, 2025, in line with the upcoming... ► Artikel lesen | |
| 28.10.25 | Shionogi lifts profit outlook on HIV royalties and overseas growth | 24 | Japan Times | ||
| 27.10.25 | Shionogi & Co. H1 Net Profit Rises, But Revenue Slips; Revises Annual Outlook | 550 | AFX News | TOKYO (dpa-AFX) - Shionogi & Company Limited (SGIOF, 4507.T), a Japanese pharmaceutical company, on Monday reported a rise in net profit for the first half, helped by an increase in finance... ► Artikel lesen | |
| 25.09.25 | Kursverluste für die Aktie von Shionogi (14,80 €) | 551 | ARIVA.de | Im Wertpapierhandel liegt der Anteilsschein von Shionogi aktuell im Minus. Zuletzt zahlten Investoren für das Papier 14,80 Euro. Die Aktie von Shionogi verzeichnet zur Stunde einen Kursrückgang von... ► Artikel lesen | |
| 22.07.25 | Aktienmarkt: Shionogi-Aktie kann sich nicht behaupten (14,00 €) | 570 | ARIVA.de | Im Wertpapierhandel notiert die Shionogi-Aktie zur Stunde etwas leichter. Der jüngste Kurs betrug 14,00 Euro. Ein Minus in Höhe von 0,6 Euro müssen derzeit die Aktionäre von Shionogi hinnehmen. Aktuell... ► Artikel lesen | |
| 02.07.25 | Adhoc: BioVersys AG: BioVersys And Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculous Mycobacteria (NTM) Clinical Candidate | 1.985 | EQS Group (EN) | BioVersys AG / Key word(s): Agreement/Partnership
BIOVERSYS AND SHIONOGI ENTER INTO GLOBAL RESEARCH COLLABORATION FOR BROAD-SPECTRUM NON-TUBERCULOUS MYCOBACTERIA (NTM) CLINICAL... ► Artikel lesen | |
| 12.05.25 | Shionogi-Aktie unter Druck: Kurs fällt um 4,76 Prozent (14,00 €) | 685 | ARIVA.de | Die Aktie von Shionogi zählt heute zu den großen Verlierern am Aktienmarkt. Das Wertpapier verbilligt sich am Montag deutlich. Ein Verlust von 4,76 Prozent zeigt die Kurstafel für das Wertpapier von... ► Artikel lesen | |
| 08.05.25 | Aktienmarkt: Shionogi-Aktie kann sich nicht behaupten (14,50 €) | 598 | ARIVA.de | An der Börse liegt die Shionogi-Aktie zur Stunde im Minus. Das Papier notiert aktuell bei 14,50 Euro. Heute hat sich im Wertpapierhandel die Aktie von Shionogi zwischenzeitlich um 1,36 Prozent verbilligt.... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TRULIEVE CANNABIS | 5,235 | +1,16 % | Trulieve Cannabis Corp.: Trulieve Reports Fourth Quarter and Full Year 2025 Results with 60% Gross Margin and Record Cash Flow Generation | Full year revenue of $1.2 billion, with 60% gross margin
Record 2025 cash flow from operations of $273 million and free cash flow of $229 million*
Record 50.1... ► Artikel lesen | |
| WEST PHARMACEUTICAL SERVICES | 210,40 | -2,14 % | Here is Why West Pharmaceutical Services, Inc. (WST) is Strongly Favored by Hedge Funds | ||
| SHIONOGI | 18,500 | -5,13 % | Cumulus Neuroscience Enters Japanese Market to Advance Novel Cognitive Biomarkers with New Customer Shionogi & Co., Ltd. | BELFAST, Northern Ireland, Feb. 10, 2026 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and... ► Artikel lesen | |
| KALA BIO | 0,347 | +3,89 % | KALA BIO, Inc.: KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint | -- Study did not meet primary endpoint of complete healing of PCED at Week 8; secondary endpoints also did not achieve statistical significance -- -- KPI-012 was well-tolerated with no treatment-related... ► Artikel lesen | |
| CHARLOTTES WEB | 0,550 | -5,17 % | Charlotte's Web Holdings, Inc.: Charlotte's Web Reports Q3 2025 Results |
Healthcare Focus, Product Innovation, and Cost Improvements
LOUISVILLE, Colo., Nov. 12, 2025 /PRNewswire/ - (TSX: CWEB) (OTC: CWBHF), Charlotte's Web Holdings,... ► Artikel lesen | |
| BEXIMCO PHARMACEUTICALS | 0,515 | 0,00 % | Beximco Pharma. - Order re Extension to Publish Financial Results | ||
| LUYE PHARMA | 0,260 | -5,11 % | LUYE PHARMA (02186): DISCLOSEABLE AND CONNECTED TRANSACTION CAPITAL INJECTION IN NANJING LUYE | ||
| MIRUM PHARMACEUTICALS | 78,00 | +1,30 % | 13 Analysts Have This To Say About Mirum Pharmaceuticals | ||
| PERCHERON THERAPEUTICS | 0,005 | +11,11 % | PERCHERON THERAPEUTICS LIMITED: Half Yearly Report and Accounts | ||
| AYURCANN | 0,001 | 0,00 % | XFRA 3ZQ0: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| AVANT BRANDS | 0,515 | +6,40 % | Avant Brands Inc.: Avant Brands Reports Audited Fiscal 2025 Results with 19% Recreational Revenue Growth | Record Operating Cash Flow: Generated $5.7 million in operating cash flow, up significantly from $0.5 million in FY 2024.Recreational Revenue Growth: Increased 19% to $14.8 million, driven by blk mkt... ► Artikel lesen | |
| KALBE FARMA | 0,048 | +7,87 % | KLBF to buyback shares, allocating IDR 250 billion: KLBF plans to repurchase shares worth IDR 250 billion over ... | ||
| EVEREST MEDICINES | 3,640 | -5,70 % | Everest Medicines Limited: Everest Medicines Shareholders Pass Resolutions Including Commercialization Service Agreement at EGM | HONG KONG, Feb 25, 2026 - (ACN Newswire) - Everest Medicines shareholders passed all proposed resolutions at an extraordinary general meeting (the 'EGM') held virtually on February 24, 2026, the company... ► Artikel lesen | |
| KOBAYASHI PHARMACEUTICAL | 31,600 | 0,00 % | Kobayashi Pharmaceutical Co., Ltd. Profit Declines In Full Year | TOKYO (dpa-AFX) - Kobayashi Pharmaceutical Co., Ltd. (KBYPF) announced earnings for full year that Dropped, from last yearThe company's earnings came in at JPY3.656 billion, or JPY49.19 per... ► Artikel lesen | |
| SILO WELLNESS | 0,008 | -100,00 % | Silo Wellness Inc.: Silo Wellness Submits CSE Listing Statement for Review of Born Defense Proposed Change of Business | Eugene, Oregon and Toronto, Ontario--(Newsfile Corp. - September 28, 2025) - Silo Wellness Inc. (CSE: SILO) ("Silo" or the "Company"), to be renamed Born Defense Inc., is pleased to announce that it... ► Artikel lesen |
Das Unternehmen SHIONOGI & CO LTD ADR kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 9,700 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHIONOGI & CO LTD ADR finden Sie auf Wallstreet Online.